Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mid-Size Japanese Pharmas Turn To U.S. Market For Sales Growth

This article was originally published in PharmAsia News

Executive Summary

Some of Japan's smaller drug makers are following their larger colleagues in seeking new or expanded markets in the United States to offset lagging sales growth at home. Dainippon Sumitomo Pharma is developing its lurasidone now in Phase III trials for the U.S. market, beginning with approval to treat schizophrenia in 2012 and later for depression. Mitsubishi Tanabe Pharma and Shionogi also are looking to the U.S. market for sales. The former plans to apply next year for its drug to treat a kidney failure symptom, while the latter seeks to market an appetite suppressant in 2012. (Click here for more - a subscription may be required
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC070859

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel